Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Kosko

Foot and Ankle Surgery Hattiesburg, MS Medical Doctor

NPI 1295937928 CMS profile 195462

3688 Veterans Memorial Dr, Suite 200, Hattiesburg, MS 39401

Open in the dashboard

General payments

$40,461

166 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Kosko of Hattiesburg, MS is reported in the CMS Open Payments database as having received $40,461 across 166 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,334 51
2024 General $3,210 11
2023 General $6,496 19
2022 General $9,666 27
2021 General $4,581 27
2020 General $1,286 10
2019 General $2,888 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Kosko
  • Foot and Ankle Surgery median
  • Middle half of Foot and Ankle Surgery
  • National median

In program year 2025, general payments to John Kosko were reported at $12,334. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.

Show as a table
Year John Kosko Foot and Ankle Surgery median Middle half National median
2019 $2,888 $1,327 $279–$5,421 $163
2020 $1,286 $795 $121–$3,473 $114
2021 $4,581 $1,289 $201–$4,963 $132
2022 $9,666 $1,539 $270–$6,067 $149
2023 $6,496 $1,117 $257–$5,264 $160
2024 $3,210 $1,064 $235–$4,944 $164
2025 $12,334 $1,183 $267–$6,309 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Linvatec Corporation $12,406 12 payments
  2. In2Bones USA, LLC $11,446 13 payments
  3. Paragon 28, Inc. $6,573 26 payments
  4. Alon Medical Technology $2,847 27 payments
  5. Wright Medical Technology, Inc. $2,742 18 payments
  6. Arthrex, Inc. $1,862 16 payments
  7. Stryker Corporation $1,116 19 payments
  8. DePuy Synthes Sales Inc. $321 4 payments
  9. Abbott Laboratories $296 8 payments
  10. Coastal Medical Technologies LLC $165 2 payments
  11. Other $685 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $20,161 19 payments
  2. Travel and Lodging $10,603 26 payments
  3. Food and Beverage $5,587 117 payments
  4. Consulting Fee $4,110 4 payments
Products named General payments · program years 2019–2025
  1. ALLOGRAFT TISSUE $7,314 7 payments
  2. CoLink $6,063 9 payments
  3. ALLOAID $5,051 4 payments
  4. PORTFOLIO $2,627 6 payments
  5. APEX 3D $2,610 9 payments
  6. INFINITY Foot And Ankle $2,501 12 payments
  7. Quantum Total Ankle $245 2 payments
  8. TriWay TTC Nail $245 2 payments
  9. INFINITY Trauma & Extremities $228 2 payments
  10. ANCHORAGE $211 3 payments
  11. Other $2,979 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

243

Median for Orthopedic Surgery: 203

Drug cost

$1,108

Median for Orthopedic Surgery: $1,433

Branded share of claims

24.7%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 40 $358
Diclofenac Sodium Generic 12 $267
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 28 $161
Doxycycline Hyclate Generic 12 $75
Ondansetron Hcl Generic 16 $61
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 32 $61
Meloxicam Generic 28 $58
Tramadol Hcl Generic 28 $47
Famotidine Generic 35 $14
Metoclopramide Hcl Generic 12 $5

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 135 billing codes

Paid by Medicare

$180,394

Of which drugs: $459

Medicare patients

706

Average age 73

Services billed

5,686

477 women, 229 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 36%
Diabetes 29%
Depression 27%
Chronic kidney disease 17%
Osteoporosis 17%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 59 3,362 $343
Injection, methylprednisolone acetate, 40 mg J1030 Office 30 35 $116

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

166 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Foot and Ankle Surgery in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record